ArticleDiscover oncology2025
Unveiling the mechanisms of Tianjihuang in hepatocellular carcinoma: a network pharmacology and molecular docking study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Naringenin restores neuronal membrane electro-biophysical homeostasis: insights from EIS circuit modeling and molecular dynamics.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited therapeutic options and poor long-term survival. Hypericum japonicum Thunb. (Tianjihuang), a traditional Chinese medicine exhibits promising anticancer properties. This study aims to elucidate the multi-target mechanisms of Tianjihuang in treating HCC using network pharmacology and molecular docking techniques.
methodsThe active components of Tianjihuang and their targets were retrieved from TCMSP, PubChem, and Swiss Target Prediction databases. HCC-related targets were identified using GeneCard, OMIM, and TTD databases, and overlapping targets were analyzed. Protein-protein interaction (PPI) networks were constructed and analyzed using Cytoscape. Functional enrichment analysis of key targets was performed via GO and KEGG pathways. Kaplan-Meier curves assessed the clinical relevance of core targets, and molecular docking evaluated the binding affinities between Tianjihuang components and key targets.
resultsTianjihuang contained seven bioactive components targeting 207 genes, with 77 overlapping HCC-related targets. PPI analysis identified key targets, including AKT1, STAT3, EGFR, and ESR1, which play pivotal roles in HCC pathogenesis. GO and KEGG analysis revealed that Tianjihuang's anti-HCC effects involve multiple biological processes and pathways, such as cell proliferation, apoptosis, and PI3K-Akt signaling. Molecular docking results showed high binding affinities of key components, such as quercetin and gallic acid, with core targets supporting their potential therapeutic effects.
conclusionThis study demonstrates that Tianjihuang exerts its anti-HCC effects through a multi-component, multi-target, and multi-pathway mechanism. These findings provide a scientific foundation for the clinical application of Tianjihuang and highlight its potential as a complementary therapy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.